Skip to main content

Table 8 Mean and median survival as calculated from Kaplan-Meier survival curves. Only IBM which gives statistical significance as demonstrated by the univariate analysis in Table 7 is included in this table

From: Leveraging hybrid biomarkers in clinical endpoint prediction

Biomarkers

5-Year Overall Survival

Mean

95% CI

Difference

Median

95% CI

Difference

Solid Composition

RDC

 SD

5.20

4.27–2.57

2.04

4.43

2.93–5.48

1.17

 NSD

3.16

2.57–3.74

3.26

2.49–3.90

LoFAR

 SD

5.50

4.46–6.61

2.23

5.20

3.11–5.24

2.00

 NSD

3.27

2.75–3.79

3.20

2.71–3.84

Solidity

 SD

4.96

4.08–5.85

1.64

3.90

2.85–5.48

0.58

 NSD

3.32

2.68–3.96

3.32

3.15–3.84

Lucent Composition

RLC

 SD

5.20

4.27–2.57

2.04

4.43

2.93–5.48

1.17

 NSD

3.16

2.57–3.74

3.26

2.49–3.90

ATR

 SD

5.05

4.11–5.99

1.69

3.78

2.76–5.48

0.46

 NSD

3.36

2.82–3.90

3.32

3.15–3.90

LoCAR

 SD

5.17

4.24–6.11

2.03

3.99

3.32–5.48

0.83

 NSD

3.14

2.59–3.69

3.16

2.49–3.84

  1. Data are presented in years